Adamas Pharmaceuticals (ADMS) had five minutes on Thursday night to feel good about its first U.S. drug approval before sniping over pricing kicked in.
The FDA approved the new Adamas product, to be marketed under the brand name Gocovri, to reduce dyskinesia (involuntary movements) experienced by some Parkinson’s disease patients on levodopa therapy. Adamas noted Thursday that Gocovri is the first and only FDA-approved medicine for this indication, but the claim comes with an asterisk.
Gocovri is an extended-release version of amantadine, a generic medicine approved to treat a type of flu but which is also commonly prescribed by doctors off label to treat dyskinesia in Parkinson’s patients.
The answer is no it should not. I wonder if it is possible to take the original in divided doses?
Comments are closed.